セマグルチド (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "セマグルチド" in Japanese language version.

refsWebsite

Global rank Japanese rank

25nih.gov

4^th place

24^th place

16doi.org

2^nd place

6^th place

7novonordisk.co.jp

low place

5europa.eu

68^th place

425^th place

5fda.gov

447^th place

1,043^rd place

3pmda.go.jp

6,690^th place

394^th place

3globenewswire.com

2,614^th place

6,858^th place

3hres.ca

low place

2tga.gov.au

3,984^th place

low place

2funnelback.com

low place

2medicines.org.uk

3,823^rd place

low place

2drugs.com

399^th place

1,603^rd place

2asahi.com

141^st place

9^th place

2nejm.org

2,374^th place

2,486^th place

1novonordisk.com

low place

1ozempicpro.com

low place

1drugbank.com

low place

1qut.edu.au

8,570^th place

low place

1cnn.co.jp

1,952^nd place

119^th place

1diabetesjournals.org

low place

1nikkeibp.co.jp

1,415^th place

95^th place

1clinicaltrials.gov

5,225^th place

low place

1wikipedia.org

low place

1ouhp-dmcenter.jp

low place

1sciencedaily.com

993^rd place

2,074^th place

1worldcat.org

5^th place

19^th place

1abc7ny.com

7,053^rd place

low place

1ajmc.com

low place

1medscape.com

719^th place

3,311^th place

abc7ny.com

“Diabetes medicine, Wegovy, approved by Food and Drug Administration for long-term weight management”. ABC7 New York (4 June 2021). 5 June 2021閲覧。

ajmc.com

“FDA Clears Semaglutide for Weight Loss When Used With Diet, Exercise”. AJMC. 5 June 2021閲覧。

asahi.com

“肥満症の薬、30年ぶり国内登場へ　米国では美容目的の利用も横行”. 朝日新聞. 2023年6月22日閲覧。
“肥満症治療薬「ウゴービ」、22日から保険適用に　厚労省”. 朝日新聞. 2023年11月16日閲覧。

clinicaltrials.gov

臨床試験番号 NCT02648204 研究名 "Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes" - ClinicalTrials.gov

cnn.co.jp

“糖尿病治療薬で脱毛や自殺願望の報告、米ＦＤＡが検証”. CNN (2024年1月4日). 2024年1月5日閲覧。

diabetesjournals.org

diabetes.diabetesjournals.org

“The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates”. Diabetes 63 (7): 2486–97. (July 2014). doi:10.2337/db13-1087. PMID 24608440.

doi.org

“Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel”. Journal of Clinical Pharmacology 55 (5): 497–504. (May 2015). doi:10.1002/jcph.443. PMC 4418331. PMID 25475122.
“Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?”. Expert Opinion on Drug Metabolism & Toxicology 14 (3): 371–377. (March 2018). doi:10.1080/17425255.2018.1441286. PMID 29439603.
“Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes”. The New England Journal of Medicine 375 (19): 1834–1844. (November 2016). doi:10.1056/NEJMoa1607141. PMID 27633186.
“Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes”. Canadian Journal of Diabetes 43 (2): 136–145. (March 2019). doi:10.1016/j.jcjd.2018.05.008. PMID 30195966.
“Semaglutide: First Global Approval”. Drugs 78 (2): 275–284. (February 2018). doi:10.1007/s40265-018-0871-0. PMID 29363040.
“Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide”. Journal of Medicinal Chemistry 58 (18): 7370–80. (September 2015). doi:10.1021/acs.jmedchem.5b00726. PMID 26308095.
“The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates”. Diabetes 63 (7): 2486–97. (July 2014). doi:10.2337/db13-1087. PMID 24608440.
“Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1-5, 2012. Berlin, Germany”. Diabetologia 55 Suppl 1 (S1): S7-537. (October 2012). doi:10.1007/s00125-012-2688-9. PMID 22918257.
“Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial”. JAMA 318 (15): 1460–1470. (October 2017). doi:10.1001/jama.2017.14752. PMC 5817971. PMID 29049653.
“Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity”. Diabetes, Obesity & Metabolism 19 (9): 1242–1251. (September 2017). doi:10.1111/dom.12932. PMC 5573908. PMID 28266779.
“Once-Weekly Semaglutide in Adults with Overweight or Obesity”. New England Journal of Medicine 384 (11): 989–1002. (March 2021). doi:10.1056/NEJMoa2032183. ISSN 0028-4793. PMID 33567185.
Frías, Juan P.; Davies, Melanie J.; Rosenstock, Julio; Pérez Manghi, Federico C.; Fernández Landó, Laura; Bergman, Brandon K.; Liu, Bing; Cui, Xuewei et al. (25 June 2021). “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes”. New England Journal of Medicine 385 (6): 503–515. doi:10.1056/NEJMoa2107519. PMID 34170647 30 June 2021閲覧。.
“Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”. Am J Cardiol. 26 (222): 121-130.. (April 2024). doi:10.1016/j.amjcard.2024.04.041.. PMID 38679221.
“Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes”. N Engl J Med.. (May 2024). doi:10.1056/NEJMoa2403347.. PMID 38785209.
“Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes”. N Engl J Med. 390 (15): 1394-1407.. (April 2024). doi:10.1056/NEJMoa2313917.. PMID 38587233.
“The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial”. J Am Coll Cardiol. S0735-1097 (24): 08156-7.. (August 2024). doi:10.1016/j.jacc.2024.08.007. PMID 39217559.

drugbank.com

go.drugbank.com

“Semaglutide”. go.drugbank.com. 2021年12月14日閲覧。

drugs.com

“Semaglutide Approval Status”. drugs.com. 2021年12月14日閲覧。
“Development Status and FDA Approval Process for semaglutide”. Drugs.com. (2017年) 24 October 2017閲覧。

europa.eu

ema.europa.eu

“Ozempic EPAR”. European Medicines Agency (EMA). 26 September 2020閲覧。
“Rybelsus EPAR”. European Medicines Agency (EMA) (29 January 2020). 26 September 2020閲覧。
“Ozempic | European Medicines Agency”. 2021年12月14日閲覧。
“Rybelsus | European Medicines Agency”. 2021年12月14日閲覧。
“Wegovy : Pending EC decision”. European Medicines Agency (11 November 2021). 13 November 2021閲覧。 Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov

accessdata.fda.gov

“FULL PRESCRIBING INFORMATION”. 2021年12月14日閲覧。
“Drug Approval Package: Ozempic (semaglutide) Injection”. U.S. Food and Drug Administration (FDA) (16 January 2018). 26 September 2020閲覧。
“Drug Approval Package: Rybelsus”. U.S. Food and Drug Administration (FDA) (10 June 2020). 26 September 2020閲覧。

fda.gov

"FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014". U.S. Food and Drug Administration (FDA) (Press release). 4 June 2021. 2021年6月5日閲覧。
"FDA approves first oral GLP-1 treatment for type 2 diabetes" (Press release). FDA. 20 September 2019. 2019年9月20日閲覧。

funnelback.com

tga-search.clients.funnelback.com

“Summary for ARTG Entry:315107 Ozempic 1 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen”. Therapeutic Goods Administration (TGA). 6 June 2021閲覧。
“Summary for ARTG Entry:346198 Rybelsus semaglutide 3 mg tablet blister pack”. Therapeutic Goods Administration (TGA). 23 February 2022閲覧。

globenewswire.com

“Wegovy (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US”. Novo Nordisk (4 June 2021). 5 June 2021閲覧。
"Novo Nordisk A/S: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes" (Press release). Novo Nordisk A/S. 9 February 2018. GlobeNewswireより2018年8月19日閲覧。
"Ozempic approved in Japan for the treatment of type 2 diabetes" (Press release). Novo Nordisk A/S. 23 March 2018. GlobeNewswireより2019年4月2日閲覧。

hres.ca

pdf.hres.ca

hpr-rps.hres.ca

“Regulatory Decision Summary – Ozempic”. Health Canada (23 October 2014). 2 April 2019閲覧。

medicines.org.uk

“Ozempic 0.25 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)”. (emc) (9 April 2021). 6 June 2021閲覧。
“Rybelsus - Summary of Product Characteristics (SmPC)”. (emc) (25 November 2020). 6 June 2021閲覧。

medscape.com

“'Stunning' Twincretin Beats Semaglutide in Type 2 Diabetes”. Medscape Medical News > Conference News > ADA 2021 (27 June 2021). 30 June 2021閲覧。

nejm.org

“Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes”. The New England Journal of Medicine 375 (19): 1834–1844. (November 2016). doi:10.1056/NEJMoa1607141. PMID 27633186.
Frías, Juan P.; Davies, Melanie J.; Rosenstock, Julio; Pérez Manghi, Federico C.; Fernández Landó, Laura; Bergman, Brandon K.; Liu, Bing; Cui, Xuewei et al. (25 June 2021). “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes”. New England Journal of Medicine 385 (6): 503–515. doi:10.1056/NEJMoa2107519. PMID 34170647 30 June 2021閲覧。.

nih.gov

pubmed.ncbi.nlm.nih.gov

“Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel”. Journal of Clinical Pharmacology 55 (5): 497–504. (May 2015). doi:10.1002/jcph.443. PMC 4418331. PMID 25475122.
“Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?”. Expert Opinion on Drug Metabolism & Toxicology 14 (3): 371–377. (March 2018). doi:10.1080/17425255.2018.1441286. PMID 29439603.
“Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes”. The New England Journal of Medicine 375 (19): 1834–1844. (November 2016). doi:10.1056/NEJMoa1607141. PMID 27633186.
“Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes”. Canadian Journal of Diabetes 43 (2): 136–145. (March 2019). doi:10.1016/j.jcjd.2018.05.008. PMID 30195966.
“Semaglutide: First Global Approval”. Drugs 78 (2): 275–284. (February 2018). doi:10.1007/s40265-018-0871-0. PMID 29363040.
“Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide”. Journal of Medicinal Chemistry 58 (18): 7370–80. (September 2015). doi:10.1021/acs.jmedchem.5b00726. PMID 26308095.
“The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates”. Diabetes 63 (7): 2486–97. (July 2014). doi:10.2337/db13-1087. PMID 24608440.
“Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1-5, 2012. Berlin, Germany”. Diabetologia 55 Suppl 1 (S1): S7-537. (October 2012). doi:10.1007/s00125-012-2688-9. PMID 22918257.
“Once-weekly glucagon-like peptide 1 receptor agonists”. The Journal of the Pakistan Medical Association 65 (7): 796–8. (July 2015). PMID 26160096.
“Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial”. JAMA 318 (15): 1460–1470. (October 2017). doi:10.1001/jama.2017.14752. PMC 5817971. PMID 29049653.
“Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity”. Diabetes, Obesity & Metabolism 19 (9): 1242–1251. (September 2017). doi:10.1111/dom.12932. PMC 5573908. PMID 28266779.
“Once-Weekly Semaglutide in Adults with Overweight or Obesity”. New England Journal of Medicine 384 (11): 989–1002. (March 2021). doi:10.1056/NEJMoa2032183. ISSN 0028-4793. PMID 33567185.
Frías, Juan P.; Davies, Melanie J.; Rosenstock, Julio; Pérez Manghi, Federico C.; Fernández Landó, Laura; Bergman, Brandon K.; Liu, Bing; Cui, Xuewei et al. (25 June 2021). “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes”. New England Journal of Medicine 385 (6): 503–515. doi:10.1056/NEJMoa2107519. PMID 34170647 30 June 2021閲覧。.
“Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”. Am J Cardiol. 26 (222): 121-130.. (April 2024). doi:10.1016/j.amjcard.2024.04.041.. PMID 38679221.
“Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes”. N Engl J Med.. (May 2024). doi:10.1056/NEJMoa2403347.. PMID 38785209.
“Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes”. N Engl J Med. 390 (15): 1394-1407.. (April 2024). doi:10.1056/NEJMoa2313917.. PMID 38587233.
“The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial”. J Am Coll Cardiol. S0735-1097 (24): 08156-7.. (August 2024). doi:10.1016/j.jacc.2024.08.007. PMID 39217559.

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

“Ozempic- semaglutide injection, solution”. DailyMed. 5 June 2021閲覧。
“Rybelsus- oral semaglutide tablet”. DailyMed. 5 June 2021閲覧。

nikkeibp.co.jp

medical.nikkeibp.co.jp

今滿仁美 (2021年11月8日). “100年たっても実らない経口インスリンの現状”. 日経メディカル. 2021年12月14日閲覧。

novonordisk.co.jp

“Ozempic®（セマグルチド）、米国で承認”. 2021年12月14日閲覧。
“Ozempic®(一般名セマグルチド)、EU で 2 型糖尿病治療薬として承認”. 2021年12月14日閲覧。
“オゼンピック®（一般名：セマグルチド（遺伝子組換え））、日本で 2 型糖尿病治療薬として承認”. 2021年12月14日閲覧。
“世界初の GLP-1 アナログ錠剤 Rybelsus® (経口セマグルチド)、米国で承認”. 2021年12月14日閲覧。
“Rybelsus® (経口セマグルチド)、成人 2 型糖尿病薬として欧州で承認”. 2021年12月14日閲覧。
“ノボノルディスク、日本において、経口セマグルチドを 2 型糖尿病治療薬として製造販売承認申請”. 2021年12月14日閲覧。
“世界初、唯一の体重管理のための GLP-1 週 1 回皮下投与製剤、Wegovy™ (セマグルチド2.4 mg)が米国で承認”. 2021年12月14日閲覧。

novonordisk.com

"Ozempic (semaglutide) approved in the US". Novo Nordisk (Press release). 5 December 2017. 2021年6月5日閲覧。

ouhp-dmcenter.jp

“世界初の経口GLP-1受容体作動薬である「リベルサス錠」（セマグルチド）が国内で製造販売承認を取得しました | 岡山県糖尿病医療連携推進事業”. 2021年12月14日閲覧。

ozempicpro.com

“Selected Important Safety Information”. www.ozempicpro.com. Novo Nordisk A/S. 2 April 2019閲覧。

pmda.go.jp

info.pmda.go.jp

“オゼンピック皮下注0.25mgSD／オゼンピック皮下注0.5mgSD／オゼンピック皮下注1.0mgSD 添付文書”. www.info.pmda.go.jp. 2021年12月14日閲覧。
“リベルサス錠3mg／リベルサス錠7mg／リベルサス錠14mg 添付文書”. www.info.pmda.go.jp. 2021年12月14日閲覧。
“リベルサス錠3mg／リベルサス錠7mg／リベルサス錠14mg インタビューフォーム”. www.info.pmda.go.jp. 2021年12月14日閲覧。

qut.edu.au

eprints.qut.edu.au

“Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?”. Expert Opinion on Drug Metabolism & Toxicology 14 (3): 371–377. (March 2018). doi:10.1080/17425255.2018.1441286. PMID 29439603.

sciencedaily.com

“Drug can dramatically reduce weight of people with obesity”. ScienceDaily. (23 October 2017) 24 October 2017閲覧。

tga.gov.au

“AusPAR: Semaglutide”. Therapeutic Goods Administration (TGA) (2 December 2020). 23 February 2022閲覧。
“Rybelsus”. Therapeutic Goods Administration (TGA) (22 February 2022). 23 February 2022閲覧。

wikipedia.org

en.wikipedia.org

臨床試験番号 NCT02648204 研究名 "Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes" - ClinicalTrials.gov

worldcat.org

search.worldcat.org

“Once-Weekly Semaglutide in Adults with Overweight or Obesity”. New England Journal of Medicine 384 (11): 989–1002. (March 2021). doi:10.1056/NEJMoa2032183. ISSN 0028-4793. PMID 33567185.